Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Neglected Tropical Disease Roadmap

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

WHO publishes brief calling for integrated approach to epilepsy treatment

Epilepsy affects over 50 million people globally and accounts for 125,000 death per year

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

WHO report provides data for high levels of antimicrobial resistance in bacteria

GLASS involved 72% of the world’s population, achieving participation from 127 countries

- PMLiVE

NHS England set to be first in world to eliminate hepatitis C by 2030

Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn

- PMLiVE

WHO and EC expand strategic plans to deliver better health security

The partnership will reinforce areas highlighted in the EU Global Health Strategy

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

- PMLiVE

WHO calls for leaders to address the global HIV response

Its key focus is to highlight inequalities that hinder progress in the goal to end AIDS by 2030

Can Cinderella save us?

Conference discusses global targets in fight against antimicrobial resistance

World Health Organization reports show AMR is one of the top ten threats to global health

- PMLiVE

Novartis and MMV to advance new malaria drug combination to phase 3 study

The announcement comes as the threat of resistance to current malaria treatments grows

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links